iX Biopharma Statistics
Total Valuation
iX Biopharma has a market cap or net worth of SGD 20.32 million. The enterprise value is 23.67 million.
Market Cap | 20.32M |
Enterprise Value | 23.67M |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
iX Biopharma has 883.34 million shares outstanding. The number of shares has increased by 0.33% in one year.
Current Share Class | n/a |
Shares Outstanding | 883.34M |
Shares Change (YoY) | +0.33% |
Shares Change (QoQ) | +0.25% |
Owned by Insiders (%) | 41.96% |
Owned by Institutions (%) | 0.10% |
Float | 480.70M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 2.96 |
PB Ratio | 4.07 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.19 |
EV / Sales | 3.97 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -3.47 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 1.20.
Current Ratio | 0.89 |
Quick Ratio | 0.65 |
Debt / Equity | 1.20 |
Debt / EBITDA | n/a |
Debt / FCF | -0.76 |
Interest Coverage | -16.96 |
Financial Efficiency
Return on equity (ROE) is -106.91% and return on invested capital (ROIC) is -31.51%.
Return on Equity (ROE) | -106.91% |
Return on Assets (ROA) | -23.69% |
Return on Capital (ROIC) | -31.51% |
Revenue Per Employee | 141,881 |
Profits Per Employee | -257,000 |
Employee Count | 42 |
Asset Turnover | 0.30 |
Inventory Turnover | 4.20 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.45% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -45.45% |
50-Day Moving Average | 0.03 |
200-Day Moving Average | 0.04 |
Relative Strength Index (RSI) | 38.57 |
Average Volume (20 Days) | 266,920 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, iX Biopharma had revenue of SGD 5.96 million and -10.79 million in losses. Loss per share was -0.01.
Revenue | 5.96M |
Gross Profit | 1.05M |
Operating Income | -7.50M |
Pretax Income | -9.99M |
Net Income | -10.79M |
EBITDA | -7.08M |
EBIT | -7.50M |
Loss Per Share | -0.01 |
Balance Sheet
The company has 1.84 million in cash and 5.20 million in debt, giving a net cash position of -3.36 million or -0.00 per share.
Cash & Cash Equivalents | 1.84M |
Total Debt | 5.20M |
Net Cash | -3.36M |
Net Cash Per Share | -0.00 |
Equity (Book Value) | 4.34M |
Book Value Per Share | 0.01 |
Working Capital | -795,000 |
Cash Flow
In the last 12 months, operating cash flow was -6.55 million and capital expenditures -274,000, giving a free cash flow of -6.83 million.
Operating Cash Flow | -6.55M |
Capital Expenditures | -274,000 |
Free Cash Flow | -6.83M |
FCF Per Share | -0.01 |
Margins
Gross margin is 17.59%, with operating and profit margins of -125.78% and -181.14%.
Gross Margin | 17.59% |
Operating Margin | -125.78% |
Pretax Margin | -167.56% |
Profit Margin | -181.14% |
EBITDA Margin | -118.88% |
EBIT Margin | -125.78% |
FCF Margin | -114.57% |
Dividends & Yields
iX Biopharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.33% |
Shareholder Yield | -0.33% |
Earnings Yield | -61.30% |
FCF Yield | -33.60% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
iX Biopharma has an Altman Z-Score of -8.52. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -8.52 |
Piotroski F-Score | n/a |